Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Clavubactin batches recalled over reduced efficacy
'This recall is because the efficacy of the product cannot be guaranteed after 12 months' - VMD.

Vets and wholesalers urged to examine their inventory immediately

The Veterinary Medicines Directorate (VMD) has issued a product defect recall alert for batches of the antibiotic Clavubactin, manufactured by Le Vet Pharma.

In a news release, the VMD writes: ‘We wish to make wholesalers and veterinary surgeons aware that Le Vet Pharma has issued a recall for batches of Clavubactin 50/12.5mg (Vm 19994/4028), Clavubactin 250/62.5mg (Vm 19994/4026), Clavubactin 500/125mg (Vm 19994/4027), all distributed by Animalcare and Dechra.

‘During routine stability testing the above-mentioned products do not fulfil the mandatory testing requirements at 24 months. This recall is because the efficacy of the product cannot be guaranteed after 12 months.’

The recall affects the following batches:

Product names Batch numbers Expiry
Clavubactin 50/12.5 mg 19D82 04-2021
  18D11 04-2020
  18G32 07-2020
Clavubactin 250/62.5 mg 19D83 04-2022
  17F46 06-2020
  17H35 08-2020
  18D13 04-2021
Clavubactin 500/125 mg 19D88 04-2022
  17C80 03-2020
  17F47 06-2020
  17H38 08-2020
  18D17 04-2021
  18D18 04-2021
  18G34 04-2022


Veterinary surgeons and wholesalers are urged to examine their inventory without delay and quarantine products subject to this recall.

For more information, please contact the relevant distributor:

Animalcare: Sameer Hashmi: shashmi@animalcare.co.uk
Dechra: Tracey Smith: tracey.smith@dechra.com

Become a member or log in to add this story to your CPD history

Greyhound Board announces change to vaccination guidance

News Story 1
 The Greyhound Board of Great Britain has published new vaccination guidance, with all greyhounds registered from 1 January, 2027 required to have the L4 leptospirosis vaccination, rather than L2.

The change comes in response to the reduced availability of the 'L2' Leptospirosis vaccine across the UK, and aims to support best biosecurity practice across the racing greyhound population.

GBGB veterinary director Simon Gower, said "While rare, Leptospirosis is a serious infectious disease that can affect both dogs and humans, so it is vital that we offer our greyhounds the broadest possible protection.  

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.